# Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

> **NCT01556815** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 40 (estimated)

## Conditions studied

- PHENYTOIN/SORAFENIB [VA Drug Interaction]
- Liver Neoplasms
- Carcinoma, Hepatocellular
- Digestive System Neoplasms
- Neoplasms by Site
- Liver Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]
- HBV

## Interventions

- **PROCEDURE:** Transarterial Chemoembolization (TACE)
- **OTHER:** Sorafenib in combination with TACE

## Key facts

- **NCT ID:** NCT01556815
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2014-05
- **Final completion:** 2015-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556815, "Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01556815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*